Browsing by Subject "BNT162b2"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout
    (Elsevier, 2021-09) Barry, Mazin; Temsah, Mohamad-Hani; Aljamaan, Fadi; Saddik, Basema; Al-Eyadhy, Ayman; Alenezi, Shuliweeh; Alamro, Nurah; Alhuzaimi, Abdullah N; Alhaboob, Ali; Alhasan, Khalid; Alsohime, Fahad; Alaraj, Ali; Halwani, Rabih; Jamal, Amr; Temsah, Omar; Alzamil, Fahad; Somily, Ali; Al-Tawfiq, Jaffar A.; Medicine, School of Medicine
    Background The Kingdom of Saudi Arabia (KSA) was the fourth country in the world to authorize the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, which it rolled out on December 17, 2020 and first targeted at healthcare workers (HCWs). This study assesses vaccine uptake among this group during the first month of its availability. Methods A national cross-sectional, pilot-validated, self-administered survey was conducted among HCWs in the KSA between December 27, 2020 and January 3, 2021. The survey included sociodemographic details, previous contact with COVID-19 patients, previous infection with COVID-19, receiving (or registering with the Ministry of Health website to receive) the COVID-19 vaccine, sources of HCWs’ information on vaccines, awareness of emerging variants of concern, and anxiety level using the 7-item Generalized Anxiety Disorder assessment. A descriptive bivariate analysis and multivariate logistic binary regression analysis were performed. The primary evaluated outcome was vaccine uptake. Results Of the 1058 participants who completed the survey, 704 (66.5%) were female, and 626 (59.2%) were nurses. Of all the respondents, 352 (33.27%) were enrolled to receive or had already received the vaccine, while 706 (66.73%) had not enrolled. In a bivariate analysis, not enrolling for vaccination was more likely in females than males (78.5% vs. 21.5%, P < 0.001), HCWs between the ages of 20 and 40 years than those >40 years (70.4% vs. 29.6%, P = 0.005), Saudi HCWs than expatriates (78% vs 22%, P < 0.001), and among HCWs who used social media as a source of information than those who did not (69.8% vs. 38.6%, P < 0.001). In a multivariate analysis, independent factors associated with uptake were being a Saudi national (aOR = 1.918, 95 %CI = 1.363–2.698, P < 0.001), working in an intensive care unit (aOR = 1.495, 95 %CI = 1.083–2.063, P = 0.014), and working at a university hospital (aOR = 1.867, 95 %CI = 1.380–2.525, P < 0.001). Conclusions A low level of vaccine uptake was observed especially in female HCWs, those younger than 40 years old, and those who used social media as their source of vaccine information. This survey provides important information for public health authorities in order to scale up vaccination campaigns targeting these HCWs to increase vaccine enrollment and uptake.
  • Thumbnail Image
    Item
    Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
    (Dove Press, 2022-07-29) Alharbi, Naif Khalaf; Al-Tawfiq, Jaffar A.; Alwehaibe, Amal; Alenazi, Mohamed W.; Almasoud, Abdulrahman; Algaisi, Abdullah; Alhumaydhi, Fahad A.; Hashem, Anwar M.; Bosaeed, Mohammed; Alsagaby, Suliman A.; Medicine, School of Medicine
    Purpose: This study was conducted to investigate antibody immune responses induced by BNT162b2 and AZD1222 human COVID-19 vaccines in Riyadh city, Saudi Arabia. Patients and methods: ELISA was used to evaluate antibodies, against the SARS-CoV-2 spike S1 protein, in serum samples from 432 vaccinated individuals at six time points: pre-vaccination (baseline), post-prime, post-boost, 6-months, and 1 year post-vaccination, and 3 weeks post a third dose. Virus microneutralization assay was used to confirm antibody responses in a subset of samples. Results: Anti-SARS-CoV-2 spike IgG were detected in most subjects post-prime, reached a peak level post-boost, and remained at high level at the 6-month follow-up. At 1 year post-vaccine, the antibody levels were low but increased to a significant level higher than the peak following a third dose. The third dose was given at an average of 250 days after the second dose. The virus microneutralization assay confirmed the neutralization activity of the induced SARS-CoV-2 IgG antibodies. The vaccines induced higher IgG titres at post-prime (p=0.0001) and 6 months (p=0.006) in previously infected individuals. An increased interval between prime and boost, more than recommended time, appeared to enhance the IgG levels (p=0004). Moreover, the vaccines induced higher IgG levels in younger subjects (p=0.01). Conclusion: These data provide insights and build on the current understanding of immune responses induced by these two vaccines; and support a third boosting dose for these COVID-19 vaccines.